BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Dr. Archana Chatterjee, dean of the Chicago Medical School, who was one of the four FDA panel “no” votes, explains her decision.

FDA advisor who voted against recommending Pfizer's Covid vaccine explains why she would ‘be first in line' to get it

There is "no known or expected causal relationship between the vaccine and Bell's palsy," the Centers for Disease Control and Prevention said Friday.

CDC will monitor for Bell's palsy among Pfizer vaccine recipients, but sees no causal relationship

The US government is expected to approve the Pfizer COVID-19 vaccine for emergency use within hours, according to reports.

US closer to approving Pfizer coronavirus vaccine for emergency use

Pfizer Inc. (NYSE: PFE) and BioNTech SE's – ADR (NASDAQ: BNTX) coronavirus vaccine candidate passed the Adcom test, with the FDA panel voting 17-4 in favor of its risk-benefit profile in individuals 16 and older.  Here's SVB Leerink analyst Geoffrey Porges' take on the dynamics of the Adcom vote.

Pfizer Analyst Breaks Down The FDA Process For Coronavirus Vaccine Candidate

White House chief of staff Mark Meadows told the head of the FDA to submit his resignation if the agency doesn't clear Pfizer's vaccine for emergency use by day's end, according to reports.

White House threatens to fire FDA chief unless Pfizer Covid vaccine approved Friday, report says

Moderna

Moderna is next in line to win FDA approval for its COVID-19 vaccine.

FDA's Pfizer COVID vaccine approval means Moderna's just days away

Hello, What a week it's been. If you had any doubts this month could be one long marathon of vaccine news, this week certainly proved the case.

The FDA is preparing to authorize Pfizer's vaccine

Food and Drug Administration Commissioner Stephen Hahn said the agency would "rapidly" authorize Pfizer and BioNTech's coronavirus vaccine — but Pfizer stock fell early Friday. The post FDA Says It Will 'Rapidly' Authorize Pfizer's Covid Vaccine; But Shares Fall appeared first on Investor's Business Daily.

FDA Says It Will 'Rapidly' Authorize Pfizer's Covid Vaccine; But Shares Fall

An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine

Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing

Alex Azar said the government is on “just the last dotting of i's and crossing of t's” before it approves the first vaccine.

Covid-19 Vaccinations Could Start ‘Monday Or Tuesday' As FDA Set To Approve Pfizer Vaccine, HHS Chief Says

In a historic development, an FDA committee overwhelmingly voted in favor Thursday of the agency approving BNT162b2, an mRNA vaccine being developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) against the coronavirus.  What Happened: FDA has informed Pfizer that the agency is rapidly working toward finalization and issuance of an emergency use authorization for its co-developed investigational vaccine, FDA Commissioner Stephen Hahn said in a Friday statement.

FDA 'Rapidly Working' On Emergency Use Authorization For Pfizer, BioNTech's Coronavirus Vaccine

Pfizer gained as much as 2.2% in early Friday trading after a panel of experts recommended that the US Food and Drug Administration approve its coronavirus vaccine for emergency use. The group, which included infectious disease experts, statisticians, and public health scientists, voted 17 to 4 on Thursday in favor of authorizing the shot for people at least 16 years old. One member abstained.

Pfizer climbs 2% as FDA nears final authorization of its COVID-19 vaccine

Here's what you need to know about the impact of Covid-19 to navigate the markets today.

Pfizer's Vaccine Will Be Authorized for Emergency Use, Azar Says

The Food and Drug Administration will grant emergency-use authorization for the COVID-19 vaccine developed by Pfizer and BioNTech, Health and Human Services Secretary Alex Azar said Friday.

Pfizer coronavirus vaccine to receive FDA emergency-use authorization: Alex Azar

Dr. Archana Chatterjee told CNBC on Friday she's "fully supportive" of emergency use authorization for people who are 18 years and older.

FDA advisor explains why she voted against recommending Pfizer's Covid vaccine for emergency use

The US Food and Drug Administration (FDA) has said it intends to authorize Pfizer and BioNTech's COVID-19 vaccine. It "will rapidly work toward finalization and issuance of an emergency use authorization" for Pfizer's shot, it said Friday morning. The vaccine would be the first to be authorized for use in the US.

The FDA says it will authorize Pfizer's COVID-19 vaccine, which could be rolled out as early as Monday

Allegiance Bancshares

BOK Financial

Bankwell Financial Group

First Hawaiian

Independent Bank

Low mortgage rates, falling provisions, vaccine news and hopes of stimulus aid bode well for banks, making it wise to invest in names like BOK Financial (BOKF) and First Hawaiian (FHB).

5 Bank Stocks to Gain Amid Potential Economic Recovery

Baker Hughes Co

Devon Energy

Diamondback Energy

Marathon Oil

Occidental Petroleum

Occidental Petroleum (OXY) is the top performing energy stock within the S&P 500 in the past 3 months with a gain of 108.6% while Devon Energy (DVN) is the next best name on the list, soaring 84.8%.

Energy Sector Up 21% in Past 3 Months: Will the Rally Last?

A key FDA advisory panel overwhelmingly endorsed the Pfizer's Covid-19 vaccine Thursday evening.

FDA chief says agency will quickly approve Pfizer's Covid vaccine for emergency use.

The Food and Drug Administration plans to finalize and issue an emergency use authorization to BioNTech and Pfizer Inc.'s experimental COVID-19 vaccine, the regulator said Friday. Shares of BioNTech gained 1.5% in premarket trading on Friday, while Pfizer's stock was up 2.1%.

FDA said it plans to issue emergency authorization to BioNTech/Pfizer's COVID-19 vaccine

Here's what really matters from the FDA advisory committee's historic vote on Thursday.

FDA Committee Gives Thumbs Up for Pfizer's COVID Vaccine: 3 Most Important Things to Know

With all eyes on its COVID vaccine candidate, another drug may have more impact on the company's fate -- and its stock price.

Here's What Investors Need To Know Before Buying Pfizer Stock For Its Coronavirus Vaccine

Pfizer Inc (NYSE: PFE and BioNTech SE (NASDAQ: BNTX) have got the green light on their COVID-19 vaccine from an external panel of experts that advise the United States Food and Drug Administration. What Happened: The Vaccines and Related Biological Products Advisory Committee (VRBPAC)  voted by a large majority of 17 to 4 in favor of giving emergency use authorization (EUA) to the companies' coronavirus vaccine.

Pfizer-BioNTech COVID-19 Vaccine Gets FDA Advisors' Nod

NEW YORK and MAINZ, GERMANY, December 10, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted (17 to 4) in support of the FDA granting Emergency Use Authorization (EUA) for the companies' COVID-19 mRNA vaccine (BNT162b2). There is one member of the Committee whose vote is not included in the 17 to 4 vote decision.

Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.

Pfizer's vaccine now has the blessing of the FDA's advisory council, an important step in moving toward approval. A panel of vaccine and infectious disease experts advising the Food and Drug Administration voted to approve Pfizer's COVID-19 vaccine for anyone 16 years and above.

News for BioNTech SE Stock (BNTX)